Welcome to our dedicated page for Livanova Plc news (Ticker: LIVN), a resource for investors and traders seeking the latest updates and insights on Livanova Plc stock.
LivaNova PLC (NASDAQ: LIVN) is a global medical technology company headquartered in London, focused on select neurological and cardiac conditions. This news page aggregates company announcements, clinical updates, investor communications, and other disclosures that LivaNova issues through press releases and related channels.
Readers can find coverage of LivaNova’s neuromodulation activities, including developments in VNS Therapy for Drug‑Resistant Epilepsy and results from the CORE‑VNS real‑world study. News items also describe health economics analyses, reimbursement decisions affecting VNS Therapy procedures under U.S. Medicare programs, and scientific presentations at major epilepsy meetings.
The feed also includes updates on LivaNova’s cardiopulmonary business and its heart‑lung support technologies, as well as information on its work in obstructive sleep apnea through proximal hypoglossal nerve stimulation and the aura6000 investigational system. Articles may highlight data from randomized controlled trials, long‑term follow‑up analyses, and presentations at specialized surgical sleep and medical conferences.
In addition, investors can follow LivaNova’s participation in healthcare investment conferences, Investor Day events, and quarterly financial result announcements, which the company often distributes via press release and webcasts. By reviewing this page, users can track how LivaNova communicates about its core Epilepsy and Cardiopulmonary businesses, its research programs, and its long‑range strategic plans.
For anyone researching LIVN stock or monitoring developments in medical technology for neurological and cardiac conditions, this news page offers a centralized view of LivaNova’s public announcements over time.
LivaNova (Nasdaq: LIVN) reported Q3 2025 revenue of $357.8M, up 12.5% reported, 11.0% constant-currency and 12.5% organic versus prior year. Cardiopulmonary revenue rose 18.0% driven by Essenz perfusion system sales and consumables; Neuromodulation rose 6.9%. U.S. GAAP diluted EPS was $0.49; adjusted diluted EPS was $1.11. Adjusted operating income increased to $80.4M from $63.6M; operating cash flow was $85.1M and adjusted free cash flow was $62.0M. The company raised full‑year 2025 guidance: revenue growth to 8.5%–9.5% (constant currency), adjusted EPS to $3.80–$3.90, and adjusted free cash flow to $160M–$180M. Essenz commercial launch initiated in China and a new director was appointed.
LivaNova (Nasdaq: LIVN) will present a general business update at the Wolfe Research Healthcare Conference in New York on Mon., Nov. 17, 2025 at 2:40 p.m. ET.
Chief Executive Officer Vladimir Makatsaria and Chief Financial Officer Alex Shvartsburg will take part in a fireside chat. The live webcast is open to registered viewers via www.livanova.com/events, with attendees advised to log on ~10 minutes early. A replay will be posted on the LivaNova website within 24 hours after the live presentation.
LivaNova (Nasdaq: LIVN) will release its third-quarter 2025 results prior to a conference call on Wednesday, Nov. 5, 2025 at 1:00 p.m. London time (8:00 a.m. ET). The company will host an audiocast of the call at www.livanova.com/events and recommends logging on about 10 minutes early to confirm setup. Telephone access: +1 833 470 1428 (U.S.) or +1 929 526 1599 (outside U.S.) using access code 817099. A replay will be posted in the Investors section of the LivaNova website immediately after the event.
LivaNova (Nasdaq: LIVN) will present scientific data at the International Surgical Sleep Society (ISSS) 2025 Annual Meeting in Indianapolis on Oct 9–10, 2025. Presentations include a five‑year analysis of the THN‑3 randomized controlled trial and 12‑month top‑line data from the OSPREY follow‑on RCT. OSPREY reported a 65% responder rate at 12 months (≥50% AHI improvement and AHI 20). The company will also host a breakfast symposium on and feature an oral presentation and poster describing proximal hypoglossal nerve stimulation (p‑HGNS) therapy and the aura6000 System.
Presenters include Dr. Alan Schwartz, Dr. Ofer Jacobowitz, and Dr. Atul Malhotra.
LivaNova (Nasdaq: LIVN) has appointed Donald (Don) Zurbay to its Board of Directors, where he will serve on the Audit and Compliance Committee. Zurbay brings over 30 years of experience in finance, accounting, and strategy, most recently serving as President and CEO of Patterson Companies after being its CFO. He previously spent nearly 13 years at St. Jude Medical in various leadership roles, including CFO.
Zurbay currently serves on the Board of Directors at Sight Sciences, chairing its Audit Committee. He holds a bachelor's degree in business accounting from the University of Minnesota. With this appointment, the LivaNova Board now comprises 11 Directors.
LivaNova (Nasdaq: LIVN), a leading medical technology company, has announced its upcoming Investor Day scheduled for November 12, 2025, from 9 a.m. to 1 p.m. EST in New York City. The event will feature presentations from key executives, including CEO Vladimir Makatsaria and CFO Alex Shvartsburg, who will outline the company's strategic roadmap and growth initiatives.
The event will be accessible both in-person (requiring advance registration) and via webcast on the company's website. Presentation materials and a replay will be made available in the Investors section of LivaNova's website following the event.
LivaNova (Nasdaq: LIVN), a medical technology company, announced its leadership team's participation in two upcoming healthcare conferences. CEO Vladimir Makatsaria and CFO Alex Shvartsburg will present business updates at the Baird 2025 Global Healthcare Conference on September 9 and the Morgan Stanley 23rd Annual Global Healthcare Conference on September 10 in New York City.
Both presentations will be accessible via webcast on the company's website, with replays available for 90 days after each event. Interested parties must register to attend the webcasts and should log on 10 minutes before the start time.
LivaNova (Nasdaq: LIVN) has launched its Essenz™ Perfusion System in China, marking a significant expansion in the world's second-largest market for heart-lung machines. The system, which received NMPA approval, has already supported over 100,000 patients globally since its February 2023 launch.
The Essenz system includes the next-generation heart-lung machine, Patient Monitor, and In-Line Blood Monitor, designed in collaboration with over 300 perfusionists worldwide. The launch is particularly significant given China's projected 185,000 adult and 23,500 pediatric extracorporeal circulation procedures in 2025, serving a market where approximately 330 million individuals are affected by cardiovascular disease.
LivaNova (Nasdaq: LIVN) reported strong Q2 2025 results and raised its full-year guidance. The company achieved revenue of $352.5 million, representing a 10.7% reported growth and 10.3% organic growth. Q2 2025 adjusted diluted EPS reached $1.05, up from $0.93 in Q2 2024.
The company's Cardiopulmonary segment grew 14.7% to $199.3 million, while Neuromodulation increased 6.2% to $151.7 million. LivaNova raised its 2025 guidance, now expecting revenue growth of 8.0-9.0% on a constant-currency basis and adjusted EPS of $3.70-$3.80.
Notable developments include initiating CMS reconsideration for VNS Therapy coverage in treatment-resistant depression and publishing positive long-term data for drug-resistant epilepsy treatment.
LivaNova (Nasdaq: LIVN), a leading medical technology company, has scheduled its second-quarter 2025 earnings conference call for August 6, 2025, at 1 p.m. London time (8 a.m. EDT). The company will release its Q2 2025 financial results before the call.
Investors can access the audiocast at www.livanova.com/events. For telephone access, U.S. participants should dial +1 833 470 1428, while international callers can use +1 929 526 1599 with access code 460430. A replay will be available on LivaNova's website for 90 days after the call.